Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a fully integrated commercial biotechnology company focused on central nervous system (CNS) and immunology treatments, announced that its management team will participate in two upcoming investor conferences in May 2026. The company will present at the RBC Capital Markets Global Healthcare Conference on May 19 in New York and at A.G.P.’s Annual Virtual Healthcare Conference on May 20. These events provide an opportunity for Tonix to discuss its recent milestones and pipeline advancements with the investment community.
The participation underscores Tonix’s progress following the approval of TONMYA (cyclobenzaprine HCl sublingual tablets 2.8 mg), the first new treatment for fibromyalgia in over 15 years. The company’s CNS commercial infrastructure supports marketed products such as Zembrace SymTouch and Tosymra for acute migraine. Tonix is also exploring the potential of TONMYA in Phase 2 clinical trials for major depressive disorder and acute stress disorder. Additionally, the CNS pipeline includes TNX-2900, a Phase 2-ready candidate for Prader-Willi syndrome, a rare disease.
Beyond CNS, Tonix is advancing immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor designed to prevent kidney transplant rejection. These candidates address significant unmet medical needs. The conferences will allow Tonix to highlight its integrated approach from discovery to commercialization.
For more details, the full press release is available at https://ibn.fm/ZZpG2. Investors can find the latest news and updates on TNXP at the company’s newsroom: https://ibn.fm/TNXP.
